{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:20:49Z","timestamp":1792095649492,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Provincial Engineering Research Center for Animal Stem Cells of Ordinary Universities","award":["2021GCZX006"],"award-info":[{"award-number":["2021GCZX006"]}]},{"name":"Guangdong Provincial Engineering Research Center for Animal Stem Cells of Ordinary Universities","award":["2021GCZX006"],"award-info":[{"award-number":["2021GCZX006"]}]},{"name":"Guangdong Provincial Engineering Research Center for Animal Stem Cells of Ordinary Universities","award":["2021GCZX006"],"award-info":[{"award-number":["2021GCZX006"]}]},{"name":"Guangdong Provincial Engineering Research Center for Animal Stem Cells of Ordinary Universities","award":["2021GCZX006"],"award-info":[{"award-number":["2021GCZX006"]}]},{"name":"Guangdong Provincial Engineering Research Center for Animal Stem Cells of Ordinary Universities","award":["2021GCZX006"],"award-info":[{"award-number":["2021GCZX006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"DOI":"10.1186\/s12917-026-05343-9","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:05:40Z","timestamp":1772247940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolomic profiling and anti-tumor function of canine NK cells in tumor interaction"],"prefix":"10.1186","volume":"22","author":[{"given":"Shi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"3","key":"5343_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"5343_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/vco.12839","volume":"20","author":"SM Schwartz","year":"2022","unstructured":"Schwartz SM, Urfer SR, White M, Megquier K, Shrager S, Dog Aging Project C, Ruple A. Lifetime prevalence of malignant and benign tumours in companion dogs: Cross-sectional analysis of dog aging project baseline survey. Vet Comp Oncol. 2022;20(4):797\u2013804.","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"5343_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9(1):175.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"5343_CR4","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663\u201376.","journal-title":"Mol Biol Rep"},{"issue":"6","key":"5343_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41551-024-01273-9","volume":"9","author":"A Papargyriou","year":"2025","unstructured":"Papargyriou A, Najajreh M, Cook DP, Maurer CH, Barthel S, Messal HA, Ravichandran SK, Richter T, Knolle M, Metzler T, et al. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Nat Biomed Eng. 2025;9(6):836\u201364.","journal-title":"Nat Biomed Eng"},{"key":"5343_CR6","doi-asserted-by":"crossref","unstructured":"Poonpanichakul T, Shiao MS, Jiravejchakul N, Matangkasombut P, Sirachainan E, Charoensawan V, Jinawath N. Capturing tumour heterogeneity in pre- and post-chemotherapy colorectal cancer ascites-derived cells using single-cell RNA-sequencing. Biosci Rep. 2021;41(12).","DOI":"10.1042\/BSR20212093"},{"issue":"8","key":"5343_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"5343_CR8","doi-asserted-by":"crossref","unstructured":"Lanier LL. Five decades of natural killer cell discovery. J Exp Med 2024;221(8).","DOI":"10.1084\/jem.20231222"},{"issue":"6","key":"5343_CR9","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","volume":"180","author":"A Crinier","year":"2020","unstructured":"Crinier A, Narni-Mancinelli E, Ugolini S, Vivier E. SnapShot: natural killer cells. Cell. 2020;180(6):1280\u20131280. e1281.","journal-title":"Cell"},{"issue":"8","key":"5343_CR10","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141(8):856\u201368.","journal-title":"Blood"},{"issue":"11","key":"5343_CR11","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"HT Khong","year":"2002","unstructured":"Khong HT, Restifo NP. Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat Immunol. 2002;3(11):999\u20131005.","journal-title":"Nat Immunol"},{"issue":"5","key":"5343_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8(5):369\u201380.","journal-title":"Cancer Cell"},{"key":"5343_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","volume":"25","author":"GA Rabinovich","year":"2007","unstructured":"Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267\u201396.","journal-title":"Annu Rev Immunol"},{"key":"5343_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0065-2776(06)90002-9","volume":"90","author":"CG Drake","year":"2006","unstructured":"Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51\u201381.","journal-title":"Adv Immunol"},{"issue":"4","key":"5343_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","volume":"54","author":"C Blank","year":"2005","unstructured":"Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54(4):307\u201314.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"5343_CR16","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42(11):1825\u201363.","journal-title":"Cancer Cell"},{"issue":"1","key":"5343_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","volume":"11","author":"B Cozar","year":"2021","unstructured":"Cozar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-Infiltrating natural killer cells. Cancer Discov. 2021;11(1):34\u201344.","journal-title":"Cancer Discov"},{"key":"5343_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-animal-022114-110911","volume":"4","author":"HL Gardner","year":"2016","unstructured":"Gardner HL, Fenger JM, London CA. Dogs as a model for cancer. Annu Rev Anim Biosci. 2016;4:199\u2013222.","journal-title":"Annu Rev Anim Biosci"},{"key":"5343_CR19","doi-asserted-by":"publisher","first-page":"106055","DOI":"10.1016\/j.tvjl.2023.106055","volume":"303","author":"LM Gherman","year":"2024","unstructured":"Gherman LM, Chiroi P, Nutu A, Bica C, Berindan-Neagoe I. Profiling canine mammary tumors: A potential model for studying human breast cancer. Vet J. 2024;303:106055.","journal-title":"Vet J"},{"key":"5343_CR20","doi-asserted-by":"publisher","first-page":"1571085","DOI":"10.3389\/fimmu.2025.1571085","volume":"16","author":"AM Razmara","year":"2025","unstructured":"Razmara AM, Lammers M, Judge SJ, Murphy WJ, Gaskill CE, Culp WTN, Gingrich AA, Morris ZS, Rebhun RB, Brown CT, et al. Single cell atlas of canine natural killer cells identifies distinct Circulating and tissue resident gene profiles. Front Immunol. 2025;16:1571085.","journal-title":"Front Immunol"},{"issue":"3","key":"5343_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/03009858221083038","volume":"59","author":"J Beck","year":"2022","unstructured":"Beck J, Ren L, Huang S, Berger E, Bardales K, Mannheimer J, Mazcko C, LeBlanc A. Canine and murine models of osteosarcoma. Vet Pathol. 2022;59(3):399\u2013414.","journal-title":"Vet Pathol"},{"key":"5343_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1146\/annurev-animal-030117-014523","volume":"7","author":"EA Ostrander","year":"2019","unstructured":"Ostrander EA, Dreger DL, Evans JM. Canine cancer genomics: lessons for canine and human health. Annu Rev Anim Biosci. 2019;7:449\u201372.","journal-title":"Annu Rev Anim Biosci"},{"key":"5343_CR23","doi-asserted-by":"publisher","first-page":"1336158","DOI":"10.3389\/fvets.2024.1336158","volume":"11","author":"AM Razmara","year":"2024","unstructured":"Razmara AM, Gingrich AA, Toedebusch CM, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Improved characterization and translation of NK cells for canine immunotherapy. Front Vet Sci. 2024;11:1336158.","journal-title":"Front Vet Sci"},{"key":"5343_CR24","doi-asserted-by":"crossref","unstructured":"Gingrich AA, Modiano JF, Canter RJ. Characterization and potential applications of dog natural killer cells in cancer immunotherapy. J Clin Med. 2019;8(11).","DOI":"10.3390\/jcm8111802"},{"key":"5343_CR25","doi-asserted-by":"crossref","unstructured":"Addissie S, Klingemann H. Cellular immunotherapy of canine cancer. Vet Sci. 2018;5(4).","DOI":"10.3390\/vetsci5040100"},{"key":"5343_CR26","doi-asserted-by":"publisher","first-page":"665784","DOI":"10.3389\/fimmu.2021.665784","volume":"12","author":"H Klingemann","year":"2021","unstructured":"Klingemann H. Immunotherapy for dogs: still running behind humans. Front Immunol. 2021;12:665784.","journal-title":"Front Immunol"},{"key":"5343_CR27","doi-asserted-by":"crossref","unstructured":"Lee J, Lee SA, Gu NY, Jeong SY, Byeon JS, Jeong DU, Ouh IO, Lee YH, Hyun BH. Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor. Biomed Res Int. 2021;2021:6690704.","DOI":"10.1155\/2021\/6690704"},{"issue":"3","key":"5343_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.vetimm.2013.06.013","volume":"155","author":"HT Michael","year":"2013","unstructured":"Michael HT, Ito D, McCullar V, Zhang B, Miller JS, Modiano JF. Isolation and characterization of canine natural killer cells. Vet Immunol Immunopathol. 2013;155(3):211\u20137.","journal-title":"Vet Immunol Immunopathol"},{"issue":"11","key":"5343_CR29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.4049\/immunohorizons.2300092","volume":"7","author":"AA Gingrich","year":"2023","unstructured":"Gingrich AA, Razmara AM, Gingrich PW, Rebhun RB, Murphy WJ, Kent MS, Brown CT, Siegel JB, Canter RJ. Missing a missing self mechanism: modeling and detection of Ly49 expression in canine NK cells. Immunohorizons. 2023;7(11):760\u201370.","journal-title":"Immunohorizons"},{"key":"5343_CR30","doi-asserted-by":"publisher","first-page":"672361","DOI":"10.3389\/fvets.2021.672361","volume":"8","author":"WC Kisseberth","year":"2021","unstructured":"Kisseberth WC, Lee DA. Adoptive natural killer cell immunotherapy for canine osteosarcoma. Front Vet Sci. 2021;8:672361.","journal-title":"Front Vet Sci"},{"issue":"1","key":"5343_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12917-019-2068-5","volume":"15","author":"Y Kim","year":"2019","unstructured":"Kim Y, Lee SH, Kim CJ, Lee JJ, Yu D, Ahn S, Shin DJ, Kim SK. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells. BMC Vet Res. 2019;15(1):339.","journal-title":"BMC Vet Res"},{"key":"5343_CR32","doi-asserted-by":"crossref","unstructured":"Razmara AM, Farley LE, Harris RM, Judge SJ, Lammers M, Iranpur KR, Johnson EG, Dunai C, Murphy WJ, Brown CT et al. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer. J Immunother Cancer. 2024;12(4).","DOI":"10.1136\/jitc-2023-007963"},{"issue":"9","key":"5343_CR33","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","volume":"69","author":"H Fujisaki","year":"2009","unstructured":"Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010\u20137.","journal-title":"Cancer Res"},{"issue":"8000","key":"5343_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"issue":"6","key":"5343_CR35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1101\/gr.229102","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res. 2002;12(6):996\u20131006.","journal-title":"Genome Res"},{"issue":"1\u20132","key":"5343_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.vetimm.2007.06.013","volume":"119","author":"HJ Schuberth","year":"2007","unstructured":"Schuberth HJ, Kucinskiene G, Chu RM, Faldyna M. Reactivity of cross-reacting monoclonal antibodies with canine leukocytes, platelets and erythrocytes. Vet Immunol Immunopathol. 2007;119(1\u20132):47\u201355.","journal-title":"Vet Immunol Immunopathol"},{"key":"5343_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.vetimm.2019.03.005","volume":"211","author":"SS Graves","year":"2019","unstructured":"Graves SS, Gyurkocza B, Stone DM, Parker MH, Abrams K, Jochum C, Gallo S, Saad M, Johnson MM, Rosinski SL, et al. Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody. Vet Immunol Immunopathol. 2019;211:10\u20138.","journal-title":"Vet Immunol Immunopathol"},{"issue":"4","key":"5343_CR38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","volume":"19","author":"F Fang","year":"2022","unstructured":"Fang F, Xie S, Chen M, Li Y, Yue J, Ma J, Shu X, He Y, Xiao W, Tian Z. Advances in NK cell production. Cell Mol Immunol. 2022;19(4):460\u201381.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"5343_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00262-004-0555-3","volume":"54","author":"J Funk","year":"2005","unstructured":"Funk J, Schmitz G, Failing K, Burkhardt E. Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Cancer Immunol Immunother. 2005;54(1):87\u201392.","journal-title":"Cancer Immunol Immunother"},{"key":"5343_CR40","doi-asserted-by":"crossref","unstructured":"Zakiryanova GK, Kustova E, Urazalieva NT, Baimuchametov ET, Nakisbekov NN, Shurin MR. Abnormal expression of c-Myc oncogene in NK cells in patients with cancer. Int J Mol Sci. 2019;20(3).","DOI":"10.3390\/ijms20030756"},{"issue":"1","key":"5343_CR41","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/imr.13384","volume":"328","author":"C Bottino","year":"2024","unstructured":"Bottino C, Picant V, Vivier E, Castriconi R. Natural killer cells and engagers: powerful weapons against cancer. Immunol Rev. 2024;328(1):412\u201321.","journal-title":"Immunol Rev"},{"key":"5343_CR42","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","volume":"10","author":"I Terren","year":"2019","unstructured":"Terren I, Orrantia A, Vitalle J, Zenarruzabeitia O, Borrego F. NK cell metabolism and tumor microenvironment. Front Immunol. 2019;10:2278.","journal-title":"Front Immunol"},{"issue":"1","key":"5343_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/imr.13316","volume":"323","author":"A Moinuddin","year":"2024","unstructured":"Moinuddin A, Poznanski SM, Portillo AL, Monteiro JK, Ashkar AA. Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment. Immunol Rev. 2024;323(1):19\u201339.","journal-title":"Immunol Rev"},{"issue":"4","key":"5343_CR44","doi-asserted-by":"publisher","first-page":"e0302231","DOI":"10.1371\/journal.pone.0302231","volume":"19","author":"ES Dhein","year":"2024","unstructured":"Dhein ES, Heikkila U, Oevermann A, Blatter S, Meier D, Hartnack S, Guscetti F. Incidence rates of the most common canine tumors based on data from the Swiss canine cancer registry (2008 to 2020). PLoS ONE. 2024;19(4):e0302231.","journal-title":"PLoS ONE"},{"issue":"4","key":"5343_CR45","doi-asserted-by":"publisher","first-page":"e0266623","DOI":"10.1371\/journal.pone.0266623","volume":"17","author":"A Flory","year":"2022","unstructured":"Flory A, Kruglyak KM, Tynan JA, McLennan LM, Rafalko JM, Fiaux PC, Hernandez GE, Marass F, Nakashe P, Ruiz-Perez CA, et al. Clinical validation of a next-generation sequencing-based multi-cancer early detection liquid biopsy blood test in over 1,000 dogs using an independent testing set: the cancer detection in dogs (CANDiD) study. PLoS ONE. 2022;17(4):e0266623.","journal-title":"PLoS ONE"},{"key":"5343_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","volume":"34","author":"GJ Yoshida","year":"2015","unstructured":"Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111.","journal-title":"J Exp Clin Cancer Res"},{"key":"5343_CR47","doi-asserted-by":"publisher","first-page":"217076","DOI":"10.1016\/j.canlet.2024.217076","volume":"597","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhao Y, Song H, Li Y, Liu Z, Ye Z, Zhao J, Wu Y, Tang J, Yao M. Metabolic reprogramming in tumor immune microenvironment: impact on immune cell function and therapeutic implications. Cancer Lett. 2024;597:217076.","journal-title":"Cancer Lett"},{"issue":"1","key":"5343_CR48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-23-0334","volume":"14","author":"C He","year":"2024","unstructured":"He C, Wang D, Shukla SK, Hu T, Thakur R, Fu X, King RJ, Kollala SS, Attri KS, Murthy D, et al. Vitamin B6 competition in the tumor microenvironment hampers antitumor functions of NK cells. Cancer Discov. 2024;14(1):176\u201393.","journal-title":"Cancer Discov"},{"issue":"1","key":"5343_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12943-024-02164-y","volume":"23","author":"J Yan","year":"2024","unstructured":"Yan J, Chen D, Ye Z, Zhu X, Li X, Jiao H, Duan M, Zhang C, Cheng J, Xu L, et al. Molecular mechanisms and therapeutic significance of Tryptophan metabolism and signaling in cancer. Mol Cancer. 2024;23(1):241.","journal-title":"Mol Cancer"},{"issue":"1","key":"5343_CR50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12967-022-03554-w","volume":"20","author":"EE Abd El-Fattah","year":"2022","unstructured":"Abd El-Fattah EE. IDO\/kynurenine pathway in cancer: possible therapeutic approaches. J Transl Med. 2022;20(1):347.","journal-title":"J Transl Med"},{"key":"5343_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res. 2020;8:49.","journal-title":"Biomark Res"},{"key":"5343_CR52","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3389\/fimmu.2020.01185","volume":"11","author":"L Zhai","year":"2020","unstructured":"Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Sosman JA, Zhang B, Wu JD, Miller SD, Meeks JJ, et al. Immunosuppressive IDO in cancer: mechanisms of Action, animal Models, and targeting strategies. Front Immunol. 2020;11:1185.","journal-title":"Front Immunol"},{"issue":"7","key":"5343_CR53","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","volume":"63","author":"GC Prendergast","year":"2014","unstructured":"Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. 2014;63(7):721\u201335.","journal-title":"Cancer Immunol Immunother"},{"key":"5343_CR54","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev-immunol-032713-120245","volume":"32","author":"B Stockinger","year":"2014","unstructured":"Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The Aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403\u201332.","journal-title":"Annu Rev Immunol"},{"issue":"17","key":"5343_CR55","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood-2018-03-838474","volume":"132","author":"SD Scoville","year":"2018","unstructured":"Scoville SD, Nalin AP, Chen L, Chen L, Zhang MH, McConnell K, Beceiro Casas S, Ernst G, Traboulsi AA, Hashi N, et al. Human AML activates the Aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood. 2018;132(17):1792\u2013804.","journal-title":"Blood"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-026-05343-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-026-05343-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-026-05343-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:02:58Z","timestamp":1775566978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12917-026-05343-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5343"],"URL":"https:\/\/doi.org\/10.1186\/s12917-026-05343-9","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were approved by the Animal Ethics Committee of Foshan University and conducted in accordance with the ethical standards of university. The project identification code is FOSU0778009. Written informed consent was obtained from the owner for the participation of their dog in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}